Joint Formulary & PAD

Terazosin hydrochloride - Benign prostatic hyperplasia

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
BNF SPC
R
Restrictions / Comments :
Important

Restricted for patients with renal or hepatic failure

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Terazosin hydrochloride
Indication :
Benign prostatic hyperplasia
Group Name :
Keywords :
BPH, LUTS, urinary tract symptoms, urinary frequency, urinary incontinence
Brand Names Include :
Hytrin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Terazosin hydrochloride is used to treat.

  • No records returned.

Committee Recommendations (1)

Where an alpha blocker is indicated, the PCN recommend one of the following as a 1st-line treatment option
- Tamsulosin (modified release) – GREEN (NOTE - prescribe as generic capsules)
- Doxazosin (immediate release) – GREEN (NOTE - XL / modified release preparations are considered BLACK)

Alfuzosin is more costly and is therefore not recommended as a 1st-line option. (NOTE - prescribe generically)

Terazosin is reserved for patients with hepatic or renal failure since no dose adjustment is required in these patient groups